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Abstract: RNA interference is a powerful method for the knockdown of pathologically   relevant 
genes. Small interfering RNAs (siRNAs) have been widely demonstrated as effective biomedical 
genetic-therapy applications for many diseases. Unfortunately, siRNA duplexes are not ideal 
drug-like molecules. Problems hindering their effective application fundamentally lie in their 
delivery, stability, and off-target effects. Delivery systems provide solutions to many of the 
challenges facing siRNA therapeutics. Due to some fatal disadvantages of viral vectors, nonviral 
carriers have been studied extensively. Aside from liposomes, nanoparticles and cationic polymer 
carriers have exhibited improved in vivo stability, better biocompatibility, and efficiency for gene 
silencing with less cellular toxicity. They may represent a promising strategy for siRNA-based 
therapies, especially as nanomaterials. The present review also summarizes other methods of 
siRNA delivery and the side effects of the nanoparticles.
Keywords: small interfering RNA, nonviral vector, gene therapy, delivery system,   nanoparticles, 
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Introduction
Since its discovery in 1998 by Fire et al, RNA interference (RNAi) has represented 
a promising new approach towards the inhibition of gene expression in vitro or 
in vivo.1–3 In 2001, Elbashir et al4 using synthetic small interfering RNA (siRNA), 
showed for the first time that RNAi also occurs in mammalian cell lines, making 
successful development of RNAi possible. Rapid progress in our understanding of 
RNAi-based mechanisms has led to the application of this powerful mechanism in the 
study of gene function, as well as therapeutic applications for disease treatment.
RNAi is mediated through approximately 21–23 nt, double-stranded siRNAs that 
trigger sequence-specific cleavage of mRNA molecules, leading to their subsequent 
degradation.5 These siRNAs are generated intracellularly through the cleavage of 
longer double-stranded RNAs,6,7 or are introduced into the cell as chemically synthe-
sized siRNA molecules.4
However, the naked siRNA molecule, with negative charges, is susceptible to 
serum nucleases, renal clearance, and nontargeted biodistribution, making cellular 
target sites more difficult to access. Thus, it has many limitations, such as poor sta-
bility, short half-life, and low efficiency. The major hurdle faced by current RNAi 
therapeutic strategies is the efficiency of the delivery system. Recently, viral deliv-
ery, such as lentivirus and adenovirus delivery, of DNA-based siRNA constructs for 
RNAi-mediated vascular endothelial growth factor (VEGF) downregulation showed 
anti-neovascularization effects in various animal models.8–10 Viral vectors are highly International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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efficient delivery systems for nucleic acids; however, the 
potential for mutagenicity, limited loading capacities, high 
production costs, and most importantly, safety risks caused 
by their inflammatory and immunogenic effects severely limit 
the applicability of viruses. These concerns have led to the 
pursuit of nonviral alternatives. Thus, the direct, systemic, 
nonviral administration of siRNA molecules that allows 
for therapeutic use is most desirable.11 Nonviral vectors are 
capable of delivering nucleic acids, including genes, siRNA, 
or antisense RNA into cells, thus potentially resulting in their 
functional expression. These vectors are considered an attrac-
tive alternative for virus-based delivery systems.12
Multiple nonviral siRNA delivery systems include 
chemical modification of siRNA, liposomes, nanoparticles 
for siRNA delivery, cell-penetrating peptides, and targeted 
delivery. Positively charged cationic liposomes and poly-
mers, such as polyethyleneimine, are currently the two major 
carriers used to complex with negatively charged siRNA 
for systemic delivery.13 Some of these novel vehicles can 
potentially overcome extracellular and intracellular barriers, 
and facilitate the site-specific delivery, cellular uptake, and 
intracellular target interactions of siRNA.14
The current review discusses the progress in the appli-
cation of nonviral systems for synthetic RNAi molecule 
delivery, with focus on the characteristics and advantageous 
properties of siRNA nanoparticle systems.
Chemical modification of siRNA
The half-life of unmodified naked siRNAs in vivo ranges in 
minutes, but this can be significantly improved to hours by 
chemical modifications.15,16 In addition, chemical modifica-
tion of siRNAs may enhance biological stability without 
adverse effects on the gene-silencing activity. Furthermore, 
modified siRNAs with superior potency reduces the dose 
required for gene silencing,10 and specific chemical modifica-
tions can minimize siRNA side effects, such as the induction 
of recipient immune responses and inherent off-targeting 
effects.17,18 Various chemical modifications to the backbone, 
nucleobases, terminals, and sugars of siRNAs have been 
reported so far, which are mainly focused on increasing its 
stability and enhancing its cellular uptake.
The most widely used siRNA modifications are on 
sugar moieties, which commonly include replacement of 
the 2′-fluoro (2′-F), 2′-O-methyl, 2′-halogen, 2′-amine,19 
and locked nucleic acid (LNA),20 all of which have shown 
significant increase in siRNA serum stability. Layzer et al21 
have demonstrated that siRNA modified with 2′-fluoro (2′-F) 
pyrimidines are more functional in cell culture and have 
greatly increased stability and prolonged half-life (24 hours) 
in human plasma, compared with 2′-OH (1 minute) con-
taining siRNAs. Jackson et al22 showed that 2′-O-methyl 
modifications to specific positions within the siRNA seed 
region reduces the number of off-target transcripts and the 
magnitude of their regulation, without significantly affecting 
the silencing of the intended targets.
The simplest approach to increase nuclease stability 
has been to modify the internucleotide phosphate linkage 
  directly.23 Phosphorothioate (P = S) modifications can be 
placed in the RNA duplex easily at any desired position and 
will enhance the stability of siRNA in nuclease environments. 
Overhoff and Sczakiel stated that phosphorothioate (PTO)-
derived oligonucleotides stimulate the physical cellular 
uptake of siRNA in human cells.24 On the other hand, siRNAs 
with boranophosphonate (P = B) backbone modifications 
have much higher nuclease resistance than unmodified ones, 
with less cytotoxicity. In addition, Hall et al25 demonstrated 
that boranophosphate siRNAs are consistently more effec-
tive than siRNAs with the widely used phosphorothioate 
  modification. Furthermore, boranophosphate siRNAs are 
at least 10 times more nuclease resistant than unmodified 
siRNAs. Therefore, the biochemical properties of bora-
nophosphate siRNAs make them promising candidates 
for RNAi-based therapeutic applications. Recently, some 
groups used the same modified siRNA to treat patients with 
age-related macular degeneration (AMD). The process has 
reached Phase II clinical trials, and it was found to have no 
observable side effects.26
To date, much of the focus has been on modifying the 
RNA backbone, and some laboratories have modified the 
siRNA bases that are centrally involved in target   recognition. 
Terrazas and Kool27 explored the effects of methyl and 
propynyl substitution on siRNA duplex stability and cellular 
RNAi activity. The results suggested that smaller 5-methyl 
substitutions do not adversely affect gene-silencing activity; 
  furthermore, this modification contributes positively to 
siRNA stability in human serum.
Terminal nucleotide modifications of the siRNA (also 
called siRNA conjugates) have also been reported as an 
efficient delivery strategy. These include peptide modi-
fication, such as transactivating transcriptional activator 
(TAT) peptide, cholesterol conjugation, folate, and aptamer 
conjugation, which offer opportunities to enhance pharma-
cological characteristics of or introduce special features to 
siRNA.28,29 Soutschek et al30 reported that if both 5′- and 
3′-terminal modifications of the sense strand are well 
modified siRNAs, they could silence the endogenous gene International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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that encodes apolipoprotein B after intravenous injection 
in mice.
Chemical modification of siRNA can increase the stability 
of the RNA duplex to nucleases, minimize the possibility of 
immunostimulatory responses, and decrease the possibility 
of off-target effects, as well as improve its pharmacody-
namic properties and delivery to target cells.31 Chemical 
modification provides solutions to many of the challenges 
facing siRNA therapeutics, but the remaining challenge 
is to find universal chemical modification strategies, or to 
predict reliably which modifications will be effective for a 
given sequence.32
Liposome-formulated delivery 
system
Liposomes are probably the most extensively used materials 
for the delivery of gene molecules ever since their ability to 
transport the preproinsulin gene to the liver33 was demon-
strated 25 years ago. Hence, their characteristics are outlined 
in detail. Liposomes, vesicles with an aqueous compartment 
enclosed in a phospholipid bilayer, can fuse with cell mem-
branes and enhance drug delivery into cells. Polar drugs can 
be entrapped in their aqueous center. When lipids combine 
with nucleic acids to form amorphous particles, they are 
known as lipoplexes.34 siRNAs can either be entrapped within 
a lipid core35 or attached to the surface of the lipid materials36 
for delivery. The liposome can protect nucleic acids from 
enzymatic degradation and deliver nucleic acids into cells by 
interacting with the negatively charged cell membrane. There 
are two kinds of liposome: neutral and cationic lipid material. 
Neutral liposomes confer low toxicity to mammalians with 
low transfection efficiency due to their surface charge. But 
cationic liposomes can cross the cell membrane and reach 
the target genes with good biocompatibility.37,38
There are two kinds of liposome, neutral and cationic, 
based on their lipid composition. Initially, neutral liposomes 
were used for in vitro and in vivo delivery of nucleic acids 
because of their low toxicity, low immunogenicity, and easy 
production. Halder et al39 examined the therapeutic poten-
tial of focal adhesion kinase (FAK)-siRNA in the neutral 
liposome 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine 
(DOPC). The results show that treatment with FAK siRNA-
DOPC results in decreased microvessel density, decreased 
expression of VEGF and matrix metalloproteinase-9, and 
increased apoptosis of tumor-associated endothelial cells 
and tumor cells.
Given that neutral liposomes confer low transfec-
tion efficiency due to their lack of surface charges, this 
  methodology was soon supplanted when cationic liposomes 
were developed in 1989.40 The cationic charge can electro-
statically combine with siRNA to achieve a more robust 
construct to improve cell entry and protect siRNA against 
serum degradation, whereas neutral lipids facilitate fusion 
with the host cell membrane.41 Spagnou et al37 selected 
a number of cationic liposome/lipid-based systems to 
investigate the optimum lipid to nucleic acid ratio, mode 
of delivery, biocompatibility, and dose-response effects. 
The results demonstrate that the systems mediate a maximal 
specific gene silencing and knockdown with significantly 
low toxicity to mammalians. Leal et al42 reported the 
development of cationic liposome (CL)-siRNA complexes 
with novel cubic phase nanostructures that exhibit effi-
cient silencing at low toxicity. This finding underscored 
the importance of understanding the membrane-mediated 
interactions between the CL-siRNA complex nanostruc-
ture and cell components in developing CL-based gene-
silencing vectors.
Some cationic liposomes, such as Lipofectamine™ 
2000, Oligofectamine™, and Lipofectamine (Invitrogen), 
are commercially available.43 Huang44 transfected two 
keratoepithelin (KE)-specific siRNAs into HEK293 cells 
via Lipofectamine to treat certain types of inherited corneal 
stromal dystrophy, and observed that KE expression is reduced 
by approximately 50%–80%. Kim et al45 applied water-soluble 
lipopolymer (WSLP) for delivering siRNA targeting VEGF in 
vitro and in vivo, which significantly increased the efficiency 
of inhibition. WSLP/siRNA complexes can efficiently protect 
siRNAs from enzymatic degradation in serum-conditioned 
media.
Many researchers studied immunoliposomes to develop 
a vehicle that can be systemically administered safely and 
repeatedly, and will deliver the siRNA specifically and 
efficiently to the targeted tissues. Pirollo et al46 engineered 
a nanosized immunoliposome-based delivery complex that, 
when systemically administered, will preferentially target 
and deliver siRNA to tumor cells wherever they occur in the 
body. They enhanced the efficiency of this complex with 
the inclusion of a pH-sensitive histidine–lysine peptide in the 
complex and by delivery of a modified anti-HER-2 siRNA 
molecule. The complex can sensitize human tumor cells to 
chemotherapeutics, silence the target gene, and inhibit tumor 
growth in a cancer model.
Successful lipoplex deliveries of siRNA has been reported 
in several studies, and mechanisms for the release of payload 
from lipoplexes have been suggested. Continued research 
into the mechanism of release may lead to the development International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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of more bioresponsive vectors that can achieve higher levels 
of silencing for a given dose.47
Nanotechnology-based siRNA 
delivery system
The birth of nanotechnology has allowed people to trans-
form nature at the molecular and atomic level, enabling the 
manipulation of single atoms. With the progress of material 
synthesis and the rise of nanotechnology, the synthesis of 
nanomaterials with specific functions has become   possible. 
The development of nanotechnology in the biological 
area has made nanodelivery systems popular. Currently, 
nanospheres can smoothly pass the blood–brain barrier, 
testicle–blood barrier, and placenta.48,49 Thus, nanospheres 
will be suitable transfection carriers for improving the effect 
of gene therapy.
Due to their low toxicity, biodegradability, and bio-
compatibility, many nanomaterials are used as transfection 
  carriers, such as chitosan, cyclodextrin, polyethyleneimine 
(PEI), poly(lactic-co-glycolic acid) (PLGA), dendrimers, 
magnetic nanoparticles, carbon nanotubes, and gold   nanorods. 
Because of its high nuclease resistance and mucoadhesive 
properties, chitosan, natural polymers extracted from crus-
taceans, has become popular siRNA vectors. Howard et al50 
used a chitosan-based siRNA nanoparticle delivery system 
for RNA interference in vitro and in vivo. They observed, 
using fluorescence microscopy, that Cy5-labeled nanopar-
ticles were rapidly uptaken by NIH 3T3 cells within 1 hour 
and are accumulated over a 24-hour period. In vivo, effec-
tive RNAi was achieved in bronchiole epithelial cells of 
transgenic enhanced green fluorescent protein (EGFP) mice 
after nasal administration of chitosan/siRNA   formulations. 
Ghosn et al51 reported the use of imidazole-modified 
  chitosan-siRNA nanoparticles to mediate gene silencing via 
either intravenous or intranasal administration. The results 
showed that intravenous delivery demonstrated significant 
knockdown of glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) enzymes in both the lungs and the liver at as low 
as 1 mg/kg siRNA dose. For intranasal delivery, significant 
silencing of GAPDH protein expression was seen in the 
lungs with only 0.5 mg/kg/day siRNA delivered over three 
consecutive days.
As a cationic polymer, PEI with its high-density charge, 
which can protect DNA from degeneration by nuclease, has 
been widely studied in gene delivery. Höbel et al11 established 
the therapeutic efficacy and safety of PEI F25-LMW/siRNA-
mediated knockdown of VEGF in tumor cells. The results 
showed that PEI F25-LMW/siRNA complexes, which can be 
stored frozen as opposed to many other carriers, represent an 
efficient, safe, and promising modality in antitumor therapy. 
Modification of PEI with several functional moieties revealed 
that PEI succinylation resulted in up to a 10-fold reduction of 
polymer toxicity compared with unmodified PEI. Moreover, 
succinylated PEI/siRNA complexes were able to induce 
remarkable knockdown of the target luciferase gene at the 
lowest tested siRNA concentration.52
In the study by Wang,53 TAT-conjugated PEGylated 
magnetic polymeric liposomes (TAT-PEG-MPLs) formed 
with superparamagnetic nanoparticles and TAT were suc-
cessfully prepared and evaluated in vitro and in vivo. The 
results indicated that TAT-PEG-MPLs were spherical 
and nonaggregated in solution, with significantly small 
mean diameters (83.2 nm) and high magnetization. In cell 
penetration tests performed through fluorescein isothio-
cyanate (FITC) labeling, the uptake of TAT-PEG-MPLs 
by MCF-7 cells was greater than that of PEG-MPLs. Most 
importantly, in vivo animal experiment, MRI, histological 
analysis, and atomic absorption spectrophotometry revealed 
that TAT-PEG-MPLs nanoparticles significantly accumu-
lated around the target site, and even inside nerve cells.
PLGA is an amorphous polymer, with molecular weights 
ranging from 5000–300,000. It can be used as medical film 
and carrier material for sustained-release dosage systems, 
with lower toxicity, less irritation, and minimal inflammatory 
responses. Luo et al54 incorporated the siRNA sequence of 
the methyl-CpG binding domain protein 1 (MBD1) plasmid 
into a PLGA-poloxamer carrier to test the therapeutic effect 
of this compound on BxPC-3 human pancreatic cancer cells. 
They found that the PLGA-poloxamer carriers can success-
fully transfect the MBD1 siRNA plasmid into tumor cells 
and that the PLGA-MBD1 nanoparticle compound can inhibit 
cell growth and induce apoptosis.
Katas et al55 incorporated PEI into PLGA particles to pro-
duce spherical, positively charged nanoparticles that are able 
to protect siRNA against nuclease degradation. Cell culture 
studies showed that PLGA-PEI nanoparticles with encapsu-
lated siRNA are more efficient in silencing the targeted gene 
than PEI alone, with certain biocompatibility.
Ladeira et al56 described a novel approach to siRNA delivery 
by single-walled carbon nanotubes. In the study, the siRNA 
delivery system showed nonspecific toxicity and transfection 
efficiency greater than 95%. This approach offers the potential 
for siRNA delivery into different types of cells, including hard-
to-transfect cells such as neuronal cells and cardiomyocytes.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Gold nanoparticles/nanorods (GNPs/GNRs) have the 
distinct advantage of being easily modified. Hence, with their 
positively charged surfaces, GNPs/GNRs can easily attach to 
negatively charged siRNA. Bonoiu et al57applied GNRs as 
siRNA delivery to explore the dopaminergic brain signaling 
pathway in vitro. Gene silencing in these cells was evident, 
with no observed cytotoxicity. Moreover, these nanoplexes 
can transmigrate across the model of the blood–brain barrier. 
However, reports about GNPs as gene carriers are rare.
Nevertheless, research regarding siRNA delivery was 
inspired by the molecular machinery within the phi29 
bacteriophage DNA packaging motor, which contains six 
copies of packaging RNA (pRNA) molecules that form a 
hexameric ring, which is the crucial part of the motor.58 
Utilizing the novel properties of this pRNA, we constructed 
pRNA dimers and trimers with potential to serve as parts 
in nanotechnology. pRNA-derived nanoparticles have 
small sizes (20–40 nm), making them particularly suited 
for in vivo systemic delivery; the optimal size range for 
cell uptake is 10–100 nm.59 Tarapore et al60 explored the 
potential of pRNA as a vehicle in carrying siRNA to target 
metallothionein-IIa (MT-IIA) messenger RNA (mRNA) 
specifically. They found that pRNA chimeras targeting MT-
IIA are localized within the GW/P-bodies, and are more 
potent than siRNA alone in silencing MT-IIA expression. 
Therefore, the pRNA system, which can assemble into 
multivalent nanoparticles, has great potential as a highly 
potent therapeutic agent.
Targeted siRNA delivery system
Targeted RNAi therapy is a relatively new approach that 
can be used to silence genes reversibly in vivo by selective 
  targeting. Targeting the diseased cell, organ, or tissue will 
increase the silencing potency of a given dose of siRNA. 
  Specific cell targeting will also prevent side effects by avoid-
ing nondiseased cells.13 Aptamers, antibodies, small peptides, 
and other ligands that bind to the signature molecules with 
high specificity and affinity have been studied extensively for 
their ability to guide siRNA to the target tissues and cells.47
Dickerson et al61 designed nanoparticles functionalized 
with peptides that specially target the erythropoietin-  producing 
hepatocellular (Eph) A2 receptor to deliver siRNAs targeting 
epidermal growth factor receptor (EGFR). The results showed 
that the nanoparticles decreased EGFR expression levels 
and significantly increased the sensitivity of this cell line to 
docetaxel. Agrawal et al62 designed dendrimer-conjugated 
magnetofluorescent nanoworms called   “dendriworms” 
as a modular platform for siRNA delivery in vivo. Their study 
showed that dendriworms carrying siRNA against EGFR 
reduced EGFR protein levels in human glioblastoma cells 
by 70%–80%; anti-EGFR dendriworms led to specific and 
significant suppression of EGFR expression.
The folate receptor is also an important target for antican-
cer drug delivery. Many anticancer drugs, such as prodrug-
enzymes, toxic proteins, liposome drugs, and nucleic acid 
molecules, including siRNA, can be combined with folic acid 
to achieve target specificity. For example, liposome-wrapped 
siRNA nanoparticles can be modified with folic acid to inhibit 
the growth of a targeted tumor.63
Aptamers are oligonucleic acid or peptide molecules 
that are normally selected from a large random sequence 
pool to bind to a specific target molecule. Chimeric RNA 
molecules that contain an RNA aptamer directly linked to 
the passenger strand of siRNA can be transcribed in vitro 
and readily purified in large quantities. Therefore, aptamers 
can enhance the ability of siRNAs to target different cells. 
To date, only a couple of aptamers have been harnessed for 
targeted siRNA delivery to specific cell populations. Some 
studies have shown enhancement of target gene silencing 
activity and specificity using aptamer–siRNA chimeras. 
Furthermore, anti-tumor activity is further enhanced by 
appending a polyethylene glycol moiety, which increases 
the circulating half-life of the chimeras.64
Other delivery systems
Lee et al65 developed pluronic/polyethylenimine shell cross-
linked nanocapsules with embedded magnetite nanocrystals 
(PPMCs) for magnetically triggered delivery of siRNA. 
PPMC/siRNA–PEG complexes were efficiently taken up 
by cancer cells upon exposure to a magnet, thereby enhanc-
ing intracellular uptake and the silencing effect of siRNA. 
The study suggests that these novel nanomaterials could be 
potentially utilized as magnetically triggered delivery of 
various nucleic acid-based therapeutic agents.
Recently, ultrasound-mediated gene delivery with nano- 
and microbubbles was developed as a novel nonviral vector 
system. This system can directly deliver plasmid DNA and 
siRNA into the cytosol without endocytosis. Therefore, these 
genes are able to escape lysosomal degradation, resulting in 
enhanced gene expression efficiency.66,67 Zhou et al68 trans-
fected plasmid DNA of pigment epithelial derived factor 
(PEDF) into human retinal pigment epithelial (hRPE) cells 
and choroidal neovascularization (CNV) animal models by 
ultrasound-mediated microbubbles. The results showed that International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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microbubbles with ultrasound irradiation could significantly 
enhance PEDF delivery compared with microbubbles or 
ultrasound alone, and that the CNV of rats was inhibited 
effectively.
Limitations and other side-effects  
of siRNA delivery
siRNA is easily degraded by enzymes in blood, tissues, 
and cells. Several types of chemically modified siRNA 
have been produced and investigated to improve   stability; 
however, target site accumulation after administration is 
still extremely low, even when stability is improved.69 
Moreover, the cost and safety of these formulations must 
also be considered,70 and many groups have found that large 
numbers of 2′-O-Me modifications (in either strand) decrease 
siRNA activity.71–73
Even though an increasing number of cationic lipo-
somes are used as nonviral-based gene vectors, studies have 
demonstrated that these liposomes still cause significant 
toxicity,74,75 such as cell contraction, mitotic inhibition, 
formation of aggregates in blood, and the tendency to induce 
inflammatory response. Some researchers have been trying 
to design new liposomal structures to reduce their cytotoxic-
ity, and found that modifying the cationic liposome structure 
can be an effective strategy for controlling its toxicity.76 
Hundreds of lipids share the common structure of a posi-
tively charged hydrophilic head and hydrophobic tail that 
are connected via a linker structure. Most of the linkages 
between the hydrophilic and hydrophobic moieties are ether, 
ester, carbamate, or amide bonds that can affect the rate of 
biodegradation.77 Moreover, their transfection efficiency 
needs further improvement for in vivo application.
Aside from studies of its efficacy, some researchers inves-
tigated the biosafety and toxicity issues of chitosan. A recent 
study by Chellat et al78 found that high chitosan/DNA nano-
particle concentrations do not induce macrophage secretion 
of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, 
IL-6, and IL-10, which showed that nanoparticles have no 
evident inflammatory activity. The toxicity of chitosan can 
be reduced by modification with the nontoxic and biocom-
patible acrylic imidazole, and additional modifications of 
the nanoparticle components helpfully reduce toxicity and 
increase transfection efficiency.79 Dabold et al80 reported 
that the in vitro toxicity of liposome–chitosan nanoparticle 
complexes (LCS-NP) in the conjunctival epithelial cell 
(CEC) line was very low. LCS-NPs were identified inside 
CECs after 15 minutes and inside primary cultures of CECs 
after 30 minutes.
Watari et al81 revealed the micro/nanosizing effect of 
materials on living organisms. Various sizes of particles, 
from 500 nm to 150 µm, were used to co-culture with human 
neutrophils, which play a central role in the initial stage of 
inflammation against foreign bodies, as probe cells. Particles 
were also inserted into the subcutaneous connective tissue in 
the abdominal region of Wistar rats. The results showed that: 1) 
the toxicity level, shown as an absolute intensity of superoxide 
production, as well as the expression of cytokines IL-1β and 
TNF-α by micro/nanoparticles is very low; 2) the reaction is 
nonspecific and any particle below cell size are regarded by cells 
as a foreign object, including neutrophils and macrophages; and 
3) for the materials as implants, there is no strong rejection and 
it is, therefore, generally   acceptable to any person.
However, other researchers reported different results. 
Nanoscale gene vectors, after being transfected into the body 
as exogenous materials, are taken up by the reticuloendothelial 
mononuclear phagocytic system, which is mainly concentrated 
in the spleen, liver, lungs, bone marrow, and lymph nodes. The 
nanoparticles could be retained in the tissues for over 30 days; 
therefore, if not effectively removed, accumulation of the nano-
sized vectors could lead to certain organ damage.82–84
Low immunogenicity is one of the unique characteristics 
of nonviral gene vectors. However, studies have shown that 
the DNA–cationic liposome complex (lipoplex) systemic 
drugs can activate the innate immune system.85 Sakurai et al86 
found that the administration of lipoplex produces a greater 
amount of inflammatory cytokines, such as IL-6, IL-12, and 
TNF-α, than adenovirus vector administration. On the other 
hand, chitosan/DNA nanoparticles and single-walled carbon 
nanotubes are not available for immune stimulation.87–89
Clinical trials
From the first in vivo evidence of RNAi-based therapeutic 
efficacy in an animal disease model in 2003,90 the pace of its 
drug development has been rapid. Most of the clinical trials 
approved by the FDA are nontargeted, designed for intravitreal 
injection or inhalation to cure age-related macular degeneration 
(AMD), a leading cause of blindness, or respiratory syncytial 
virus (RSV), the leading cause of pediatric hospitalizations in 
the United States today. These trials with naked siRNA have 
shown certain results without untoward toxicity.14,91
Multiple nanoparticle formulations of siRNA for oncol-
ogy are currently under clinical development.92 The first 
targeted-delivery siRNA therapeutic agent approved by the 
US Food and Drug Administration (FDA) is CALAA-01, 
a PEGylated, transferrin-targeted nanoparticle that can 
combine siRNA molecule with the transferrin receptor on International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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the tumor cell surface. This is currently being investigated 
clinically in patients with solid cancers in the United States.93 
The results demonstrate that the siRNA nanoparticles are able 
to provide transient inhibition of tumor growth.
Atu027 is a liposomal formulation of siRNA against 
protein kinase N3, developed by Silence Therapeutics AG, 
and is currently being investigated in Phase I clinical trials 
in Germany.94  Atu027 comprises neutral fusogenic and PEG-
modified lipid components with improved pharmacokinetic 
properties, cellular uptake, and efficient siRNA release from 
endosomes after endocytosis.95
ALN-VSP, a nontargeted liposomal formulation of two 
siRNAs targeting kinesin spindle protein and VEGF, is in 
clinical development in the United States for the treatment of 
liver cancers. Due to interests in the potent, promising, and 
novel siRNAs and the need to protect them from degradation 
within the circulation, interest and research into nanoparticle 
formulations of nucleic acids is likely to grow continually.92
Perspective of nonviral vector
siRNA technology, which is attracting much interest in the 
research community, holds great promise as a therapeutic 
intervention for targeted gene silencing in cancers and other 
diseases. Several siRNA-based therapeutic agents are already 
in clinical trials. Further development of siRNA therapy 
depends on the development of safe and effective carriers 
for systemic administration. As described in the present 
study, cationic nanoparticles have emerged as one of the 
most attractive carriers because of their ability to form 
complexes with negatively charged siRNA and their high 
transfection   efficiency. As a whole, the transfection efficiency 
reported thus far for nonviral approaches is still below that 
of the highly efficient viral vectors. Further improvements 
to increase the efficiency and reduce the toxicity of nonviral 
vectors are needed before their clinical significance can be 
maximized. Therefore, to achieve more efficient, long-  lasting, 
and nontoxic gene delivery vectors, optimized delivery sys-
tems still have many challenges to overcome.
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